Drug Search Results
More Filters [+]

Flunarizine

Alternative Names: flunarizine, gradient, xen-007, xen007, xen 007, FLUNARIZINA
Latest Update: 2024-02-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: H1 Antagonist,Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Denmark | Dominican Republic | Ecuador | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Switzerland | Taiwan | Turkey | United Kingdom | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Flunarizine

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Intestinal Diseases|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12616000437460

P1

Completed

Liver Cirrhosis|Intestinal Diseases

2022-06-15

Recent News Events